Mealey's (April 6, 2018, 12:49 PM EDT) -- WASHINGTON, D.C. — A patent infringement defendant at oral arguments on April 5 told the Federal Circuit U.S. Court of Appeals that a Delaware federal judge committed reversible errors of law in finding that a patented formulation of zolmitriptan suitable for intranasal administration was nonobvious (Lannett Holdings Inc. v. Impax Laboratories Inc., et al., No. 17-2020, Fed. Cir.)....